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Abstract: Hypertrophic osteoarthropathy (HOA) is characterized by
clubbing of digits and, in more advanced stages, by periosteal new
bone formation and synovial effusions. Secondary HOA typically
occurs in the setting of intrathoracic malignancy, infections or lung
metastases. We report a case with an atypical presentation of HOA.
The prominent systemic signs, presentation limited to lower extrem-
ities only and an excellent response to bisphosphonates make this
case unusual.
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CASE REPORT
A 43-year-old African American man with past medical
history significant for stage IIIB non-small cell lung cancer
(adenocarcinoma histology), presented 6 months after his
initial diagnosis to our hospital with complaints of increasing
bilateral lower extremity pain and swelling for 3 weeks
(Figures 1A, B). The pain was worse on ambulation. He also
had a high grade intermittent fever for 1 week before presen-
tation. He had been evaluated and treated twice with oral
antibiotics for presumed cellulitis, with no improvement. In
addition to lower extremity edema, erythema, elevated skin
temperature, and tenderness which extended from his knees
to the toes, he was noted to have bilateral clubbing of the
digits (Figure 2). There was no swelling or tenderness of the
wrists or forearms. Doppler examination was negative for
venous thrombosis twice. He was started on intravenous
antibiotics. After 5 days of treatment he continued to be
symptomatic with swelling, erythema, warmth, exquisite ten-
derness, and fevers. He required very high doses of narcotics
to control the lower extremity pain.
Since the patient had clubbing, radiographs of the right
and left tibia were obtained, which revealed diffuse periosteal
thickening bilaterally. A bone scan revealed diffuse and
intense symmetric uptake involving bilateral femurs and
bilateral tibia confirming the diagnosis of hypertrophic osteo-
arthropathy (HOA) (Figure 3). His antibiotics were stopped
and he was treated with nonsteroidal anti inflammatory drugs
and 90 mg of pamidronate infused intravenously over 1 hour.
After 4 days the patient was free of pain. After 12 days, the
lower extremity swelling had completely resolved. Four
months after the treatment the patient remained asymptom-
atic, with no erythema or swelling by clinical examination.
DISCUSSION
HOA is characterized by periostosis of long bones,
joint pain, and clubbing; it may be primary, also known as
pachydermoperiostosis, or secondary to a variety of disease
processes.1 Primary HOA is an autosomal dominant disorder
that presents in otherwise healthy children as clubbing, peri-
ostosis, and skin manifestations including thickening of the
skin of the face and scalp, coarsening of facial features,
hyperhidrosis, and seborrhea. Like primary HOA, secondary
HOA may also present as the full spectrum of HOA or as
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FIGURE 1. A and B, Bilateral lower extremities with diffuse
edema, erythema and tenderness.
Journal of Thoracic Oncology • Volume 4, Number 2, February 2009260
isolated finger clubbing. HOA can be a significant presenting
symptom for up to 20% of primary lung tumors.2 Resolution
of the syndrome has been reported upon tumor resection. The
medical conditions that can give rise to secondary HOA are
diverse, and include primary intrathoracic neoplasms, pulmo-
nary metastases, pulmonary infections, and cyanotic heart
disease.3
Theories to explain the pathogenesis of HOA abound.
Most have not explained the development of HOA in varied
associated clinical situations. Increased circulating levels of
vascular endothelial growth factor have been identified in
patients with HOA with lung cancer and recognized as the
putative growth factor implicated in the pathogenesis of
HOA.4 Further, given the inflammatory signs associated with
HOA, COX2-derived PGE2 could have a role in HOA patho-
genesis as well.3 Others have suggested that the release of the
platelet derived growth factor is a factor in the pathogenesis
of HOA.5 The laboratory abnormalities in HOA are nonspe-
cific and reflect the underlying disorder. Radiographs show a
faint radiolucent line beneath the new periosteal bone along
the shaft of long bones bilaterally at their distal end. These
changes are observed most frequently at the wrists, ankles
and knees.5 The treatment is to identify the underlying dis-
order and treat it appropriately. The symptoms and signs of
HOA may disappear completely with removal or effective
chemotherapy of a tumor6 or with antibiotic therapy and
drainage of a chronic pulmonary infection like lung abscess
or empyema.
Disodium pamidronate is a potent inhibitor of oste-
oclastic bone resorption, which is thought to be responsible
for its therapeutic effect. Pamidronate has been used to treat
conditions with increased osteoclastic activity.7 The activa-
tion of endothelial cells and platelets occurring with neovas-
cular proliferation seems to be a key feature of HOA that may
contribute to increased osteoclastic activity.8 Some recent
reports demonstrate that pamidronate significantly improved
FIGURE 2. Clubbing of the fingers as an important diag-
nostic clue.
FIGURE 3. Bone scan showing diffuse symmetric uptake
involving bilateral femurs and tibia.
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symptoms in patients with aggressive HOA.8–10 In the met-
astatic cancer setting if the primary tumor does not respond to
systemic therapy, it is vital to control symptoms associated
with HOA by another means. Thus, our case adds to the
accumulating literature that supports the use of pamidronate
for the symptomatic relief in aggressive presentation of HOA.
In addition, this case serves as a reminder for aggressive and
atypical presentations of HOA which can masquerade an
infectious or another inflammatory process.
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